tiprankstipranks
Trending News
More News >

Mineralys Therapeutics price target lowered to $48 from $52 at Guggenheim

Guggenheim analyst Seamus Fernandez lowered the firm’s price target on Mineralys Therapeutics (MLYS) to $48 from $52 and keeps a Buy rating on the shares. The firm, which is updating its model after Q1 earnings and catching up with management, says results were “largely incremental,” but highlights that Mineralys expects to have a pre-NDA meeting with the FDA in Q4 to ensure the agency and the company are aligned on expectations for the NDA package for lorundrostat.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue